Cargando…
METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy
Non-alcoholic fatty liver disease (NAFLD) is an emerging risk factor of hepatocellular carcinoma (HCC). However, the mechanism and target therapy of NAFLD-HCC are still unclear. Here, we identify that the N(6)-methyladenosine (m(6)A) methyltransferase METTL3 promotes NAFLD-HCC. Hepatocyte-specific M...
Autores principales: | Pan, Yasi, Chen, Huarong, Zhang, Xiang, Liu, Weixin, Ding, Yanqiang, Huang, Dan, Zhai, Jianning, Wei, Wenchao, Wen, Jun, Chen, Danyu, Zhou, Yunfei, Liang, Cong, Wong, Nathalie, Man, Kwan, Cheung, Alvin Ho-Kwan, Wong, Chi Chun, Yu, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439254/ https://www.ncbi.nlm.nih.gov/pubmed/37586322 http://dx.doi.org/10.1016/j.xcrm.2023.101144 |
Ejemplares similares
-
Targeting m(6)A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer
por: Bao, Yi, et al.
Publicado: (2023) -
Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells
por: Bai, Xiaowu, et al.
Publicado: (2022) -
Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
por: Zhou, Qiming, et al.
Publicado: (2023) -
Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives
por: Pan, Yasi, et al.
Publicado: (2020) -
Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
por: Jeong, Seogsong, et al.
Publicado: (2023)